Hereditary Breast Cancer Gene Mutation Panel, NGS (BreastNext®)
Breast cancer (BC) is one of the most common malignancies and the leading cause of death among women worldwide. Hereditary BC accounts for about 10-20% of cases and is suggested by onset at a young age, bilateral breast cancer, multiple primaries and/or a history of first or second- degree family members with similar diagnoses. Mutations in the BRCA1 and BRCA2 genes are responsible for two thirds of hereditary BC, being the most well-known cause of inherited cancer predisposition. The cumulative risk of developing BC by the age of 70 for a BRCA mutation carrier is 65% for BRCA1 and 45% for BRCA2.
The BRCA1 and BRCA2 genes encode for a protein that acts as a tumor suppressor protein. Tumor suppressor proteins help prevent cells from growing and dividing too rapidly or in an uncontrolled way. BRCA1 is located in the long (q) arm of chromosome 17 at position 21.31 and BRCA2 in the long (q) arm of chromosome 13 at position 13.1. Both the BRCA1 and BRCA2 proteins are involved in repairing damaged DNA and play a critical role in maintaining the stability of a cell's genome. Mutations in the BRCA1 gene are associated with an increased risk of several types of cancer including breast cancer in both men and women. Most mutation in BRCA1 and BRCA2 genes lead to the production of truncated versions of the BRCA1 and BRCA2 proteins or result in total absence of the proteins. As a result, the proteins are unavailable to help repair damaged DNA and allow mutations to accrue. As defects accumulate, they can trigger neoplastic cell growth and division. Other genes associated with hereditary breast cancer include ATM, BARD1, CDH1, CHEK2, NF1, PALB2, PTEN, STK11, and TP53.
The ATM gene encodes for a member of the PI3/PI4-kinase family which activates cellular responses to DNA double-strand breaks and plays a crucial role in DNA damage-repair pathways. The mutations in the ATM gene that causes ataxia-teleangiectasia (AT) have also been linked to increased breast cancer risk based on epidemiological studies of (AT) families that demonstrated an increased incidence of breast cancer in women who are heterozygous carriers of an AT mutation.
The Checkpoint kinase 2 (CHEK2) gene, located on chromosome 22, is also a tumor suppressor gene involved in DNA repair and apoptosis. CHEK2 loss of function mutations are implicated in several different types of cancer, including breast cancer. Inherited mutations in the CDH1 gene have been demonstrated to increase a woman's risk of developing lobular breast cancer. CDH1 gene is located in the long (q) arm of chromosome 16 at position 22.1. This gene encodes epithelial cadherin or E-cadherin, which acts as a tumor suppressor protein. A lack of this protein, which is critical for cell adhesion, may also make it easier for cancer cells to detach from a primary tumor and metastasize to other parts of the body. The STK11 gene (also called LKB1) is located in the short (p) arm of chromosome 19 at position 13.3 and encodes a protein kinase known as serine/threonine kinase 11. This enzyme acts as a tumor suppressor by promoting apoptosis. In addition to its role as a tumor suppressor, serine/threonine kinase 11 functions appear to be required for normal development before birth. Inherited mutations in the STK11 gene cause Peutz-Jehgers syndrome (PJ) which increases the risk of developing several types of cancer. Women with PJ have 1 3-4-fold increase in their lifetime risk of developing breast cancer. PALB2 (Partner and Localizer of BRCA2) was first identified as a protein that interacts with BRCA2 and later, with BRCA1. Loss of activity of PALB2 is associated with Fanconi’s anemia as well as breast and pancreatic cancer. PTEN (phosphatase and tensin homolog deleted from chromosome 10) is a tumor suppressor gene affecting cell survival, proliferation and apoptosis. Loss of PTEN function has been correlated with many primary and metastatic malignancies, including breast cancer.
The TP53 gene regulates cell proliferation, cell repair and apoptosis and it is located on the short arm of the chromosome 17. Mutations TP53 are found altered in 20–40% of BC cases and loss of TP53 appears to be an early event in many cases of breast cancer development.
Panel Components
Although it depends on the laboratory and the clinical utility, this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, and TP53 associated with hereditary breast cancer.
- For the diagnosis and management of hereditary breast cancer
- Identification of familial BRCA1, BRCA2, TP53, PTEN, CDH1, STK11 and PALB2 mutation to allow for predictive testing in family members
No pathogenic variants or mutations were detected
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Med Pharm Rep. 2019; 92: 220–225. [PMID: 31460501]
- Breast Cancer. 2017;9: 331-335. [PMID: 28553140]
- Anticancer Res. 2014;34: 1387-400. [PMID: 24596386]
- N Engl J Med. 2014;371: 497-506. [PMID: 25099575]
- J Pathol. 2013;230: 347-9. [PMID: 23620175]
- Oncol Rep. 2013;30: 1019-29. [PMID: 23779253]
- FEBS Lett. 2011;585: 944-51. [PMID: 21192934]
- Mol Cancer Res. 2006;4: 843-9. [PMID: 17114342]
- JAMA. 2006;295: 1379-88. [PMID: 16551709]
- Hum Mutat. 2003;21: 292-300. [PMID: 12619115]
- Mutat Res. 2000;462: 167-78. [PMID: 10767628]